NGL Fine - Chem Ltd. இன் கணக்கு குறிப்புகள்

Mar 31, 2018

1. CORPORATE INFORMATION

NGL Fine-Chem Limited (The Company) is a public company domiciled in India and incorporated under the provisions of the Companies Act, 1956. Its shares are listed on the Bombay Stock Exchange. The Company is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. The Company caters to various global companies to custom manufacture high quality pharmaceuticals.

a) The company has one class of equity shares having a par value of Rs. 5 each. Each shareholder is eligible for one vote per share held. Dividend, if any, proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

Notes:

Capital Reserve: It represents the gains of capital nature which mainly includes the excess of value of net assets acquired over consideration paid by the Company for business amalgamation transaction in earlier years.

Share Premium: This is the difference between the face value of the equity shares and the consideration received in respect of shares issued.

General Reserve: The company created a General Reserve in earlier years pursuant to the provisions of the Companies Act wherein certain percentage of profits were required to be transferred to General Reserve before declaring dividends. As per Companies Act, 2013, the requirement to transfer profits to General Reserve is not mandatory. General Reserve is a free reserve available to the company.

Amalgamation Reserve was created when certain statutory reserves needed to be maintained by the transferee company during the scheme of amalgamation, which were previously maintained in the books of transferor company.

Terms and conditions of loans

1. Term Loans from HDFC Bank are @ 9.25% interest per annum and repayment to be made in 60 monthly instalments, secured by exclusive mortgage & charge on all of the companys assets including moveable & immovable property, hypothecation of inventories and book debts and guaranteed by Rahul Nachane & Rajesh Lawande, Directors of the company.

2. For Vehicle Loans

(i) Bank of Maharashtra Vehicle loan is at 10.50% interest per annum and repayable in 36 instalments and secured by hypothecation of the vehicle

(ii) HDFC Bank loan is at 9.98% interest per annum and repayble in 60 instalments and secured by hypothecation of the vehicle.

(iii) Axis Bank loan is at 8.55% interest per annum and repayble in 48 instalments and secured by hypothecation of the vehicle.

(a) Working capital loans are guaranteed by Mr. Rahul Nachane, Managing Director and Mr. Rajesh Lawande, Executive Director.

(b) Working capital loans comprise of loans repayable on demand in the form of cash credit, pre shipment finance and post shipment finance. These are secured by hypothecation of inventories, trade receivables and book debts.

There is no principal amount and interest amount overdue to Micro and Small industries. This information as required to be disclosed under the Micro, Small & Medium Enterprises Development Act, 2006, has been determined to the extent such parties have been identified on the basis of information available with the company. This information has been relied upon by the auditors.

(iii) Short term benefits (leave encashment)

The company has provided for accumulated compensation absences (leave encashment) as per Ind AS 19 "Employee Benefits". The provision is made on the basis of actuarial evaluation carried out. The current years provision is charged under Salaries and Wages as given below. This liability is not funded.

Note: In the case of present key managerial personnel, remuneration does not include gratuity and leave encashment benefits which are determined for the company as a whole.

2. Fair values

Fair value measurement includes both the significant financial instruments stated at amortised cost and at fair value in the statement of financial position. The carrying values of current financial instruments approximate their fair values due to the short-term maturity of these instruments and the disclosures of fair value are not made when the carrying amount of current financial instruments is a reasonable approximation of the fair value. The carrying values of the long-term financial instruments approximates the fair values as the management has considered the fair value measurement techniques using the observable data i.e. the discounting rate which was similar as to rates, tenure and the credit rating of the other instruments of the Company. The management has also considered the effect of time value of money with respect to other long term financial instruments by taking the Company''s fixed deposit rate of the Company.

3. Financial risk management objectives and policies

The Company''s activities expose it to a variety of financial risks: market risk,credit risk and liquidity risk. The Company’s risk management assessment and policies and processes are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor such risks and compliance with the same.

The Company has constituted a Risk Management Committee consisting of majority of directors and senior managerial personnel. The Company has a robust risk management policy to identify, evaluate business risks and opportunities. This policy seeks to create transparency, minimise adverse impact on the business objectives and enhance the Company''s competitive advantage.

The sensitivity analysis in the preceeding sections relate to the position as at March 31, 2018 and March 31, 2017.

The following assumption have been made in calculating the sensitivity analysis:

The sensitivity of the relevant profit or loss items is the effect of the assumed changes in respective market risks.

4. Credit risk

Credit risk arises from the possibility that customers may not be able to settle their obligations as agreed and arises principally from the Company''s receivables from customers, loans and investments.Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the credit worhtiness of counterparty to which the Company grants credit terms in the normal course of business.

Investments

The Company limits its exposure to credit risk by investing in liquid securities which primarily include mutual fund units. The Company does not expect any losses from non-performance of these securities and does not have any significant concentration of exposures to specific industry sectors or specific country risks.

Trade receivables

Trade receivables are typically unsecure and derived from revenue earned from customers. On account of adoption of Ind AS 109, the Company uses expected credit loss model to assess the impairment loss or gain, however this is modified if in the past experience of the company, there is likely mitigation of the credit risk.

5. Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: currency risk, interest rate risk and other price risk, such as equity price risk and commodity risk. The value of a financial instrument may change as a result of changes in the interest rates, foreign currency exchange rates, equity price fluctuations, liquidity and other market changes. Financial instruments affected by market risk include loans and borrowings, deposits and investments.

6. Foreign currency risk

Foreign exchange risk arises on future commercial transactions and on all recognised monetary assets and liabilities, which are denominated in a currency other than the functional currency of the Company. The Company’s management has set policy wherein exposure is identified, benchmark is set and monitored closely, and accordingly suitable hedges are undertaken. The Company’s foreign currency exposure arises mainly from foreign exchange imports and exports, primarily with respect to USD.

Interest rate sensitivity

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market rates. The Company’s exposure to the risk of changes in market rates relates primarily to the Company’s debt obligations with floating interest rates.

Cash flow sensitivity analysis for variable-rate instruments:

A reasonably possible change of 100 basis points in interest rates at the reporting date would have increased (decreased) profit or loss before tax by the amounts shown below. This analysis assumes that all other variables, in particular foreign currency exchange rates, remain constant:

7. Liquidity risk

Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they become due. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements.

The Group manages the liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities. The Group invests its surplus funds in bank fixed deposits and liquid schemes of mutual funds which carry limited mark to market risks. The Company also invests in equity schemes of mutual funds which carry liquidity and rate return risks.

At present, the Company expects to repay all liabilities at their contractual maturity. In order to meet such cash commitments, the operating activity is expected to generate sufficient cash inflows

8. Capital management

For the purpose of the Company''s capital management, capital includes issued equity capital, share premium and all other equity reserves attributable to the equity holders of the compnany. The primary objective of the Company''s capital management is to maximise the value of shareholder.

The Company monitors capital using Capital Gearing Ratio, which is net debt divided by total capital plus net debt. Net debt includes loans and borrowings, trade and other payables, less cash and cash equivalents.

To achieve the overall objective, the Company’s capital management aims to ensure that it meets the financial covenants attached to loans and borrowings. Breaches in meeting the covenants would permit the bank to immediately call loans and borrowings. There have been no breaches in the financial covenants of any loans and borrowings in the current year.

9. Income tax

The major components of income tax expense for the years are:

The tax rate used for the reconciliations above is the corporate tax rate of 33.063% payable by corporate entities in India on taxable profits under tax law in the Indian jurisdiction.

10. Additional information

(a) Earnings per share (EPS)

Basic EPS amounts are calculated by dividing the profit for the year attributable to equity holders by the weighted average number of equity shares outstanding at the end of the year.

Diluted EPS amounts are calculated by dividing the profit attributable to equity holders by the weighted average number of equity shares outstanding at the end the year plus the weighted average number of equity shares that would be issued on conversion of all the dilutive potential equity shares into equity shares.

11. Segmental information

As the Company’s business activities fall within a single primary business segment namely pharmaceuticals, the disclosure requirements of Ind AS 108 in this regard are not applicable.

12. Remeasurement of security deposit

Under IGAAP, interest-free lease security deposits (that are refundable in cash on completion of lease term) are recorded at their transaction value. Under Ind AS, all financial assets are required to be recognised at fair value. Accordingly, the Company has recorded these security deposits at fair value under Ind AS. Differences between the fair value and the transaction value of the security deposits have been recognised as prepaid rent. Consequent to this change , the amount of security deposits decreased by Rs. 5,72,431 at March 31, 2018 and decreased by Rs.702,551 as at March 31, 2017. The prepaid rent increased by Rs.5,32,064 as at March 31, 2018. Prepaid rent as on March 31, 2017 amounted to Rs.667,217. Due to the discounting of security deposits and unwinding of interest income, the profit for the year as at March 31, 2018 decreased by Rs.1,36,818.

13. Classification and presentation of assets and liabilities

Under IGAAP, the Company was not required to present its assets and liabilities bifurcated between financial assets/ financial liabilities and non-financial assets/ non-financial liabilities. Under Ind AS, the Company is required to present its assets and liabilities bifurcated between financial assets/ financial liabilities and non-financial assets/ non-financial liabilities. Accordingly, the Company has classified and presented the assets and liabilities.

In the opinion of the management, the current assets, loans & advances have been stated at realizable value. Provision for all the known liabilities is adequate and not in excess of the amount reasonably necessary.

14. Subsequent events

The Company evaluated all events and transactions that occurred after March 31, 2018 through May 18, 2018; the date on which the financial statements are issued. Based on the evaluation, the Company is not aware of any events or transactions that would require recognition or disclosure in the financial statements.

15. The previous years figures have been recast, regrouped and rearranged whereever necessary.

---

Mar 31, 2016

(e) Rights, preferences and restrictions attached to equity shares

The company has one class of equity shares having a par value of Rs. 5 each. Each shareholder is eligible for one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

Terms and conditions of loans

1. Term Loans from HDFC Bank are @ 10.65% interest per annum and repayment to be made in 12 monthly installments, secured by exclusive mortgage & charge on all of the company’s assets including moveable & immovable property, hypothecation of inventories and book debts and guaranteed by Rahul Nachane & Rajesh Lawande, Directors of the company.

2. Term Loans from Bank of Maharashtra were @ 12% interest per annum and repayment to be made in 60 monthly installments, secured by exclusive mortgage & charge on all of the company’s assets including moveable & immovable property, hypothecation of inventories and book debts and guaranteed by Rahul Nachane & Rajesh Lawande, Directors of the company.

3. For Vehicle Loans

(i) Bank of Maharashtra Vehicle loan is at 10.50% interest per annum and repayable in 36 installments and secured by hypothecation of the vehicle.

(ii) HDFC Bank loan is at 9.98% interest per annum and repayable in 60 installments and secured by hypothecation.

Repayment Terms :

Secured by exclusive mortgage & charge on all of the company’s assets including moveable & immovable property, hypothecation of inventories and book debts and guaranteed by Rahul Nachane & Rajesh Lawande, Directors.

(a) Long Term Retirement Benefits

Long term retirement benefits comprise of contributions to the Provident Fund and Gratuity Fund

(i) Contribution to Provident Fund: Contributions to the Provident Fund is made by the company to the Employees Provident Fund Organization, Government of India

(g) Related Parties Disclosures

Disclosures as required by Accounting Standards 18 - “Related Party Disclosures” are given below

(h) Segment Reporting

Based on the guiding principles given by the Accounting Standard - 17, "Segment Reporting" issued by the Institute of Chartered Accountants of India, the company''s business comprises of only one segment - pharmaceuticals. Hence segment wise analysis is not given as the same is not applicable.

(i) MSMED Act

The company has not received any information from suppliers or service providers, whether they are covered under the "Micro, Small and Medium Enterprises (Development) Act 2006" (MSMED Act). Therefore it is not possible to give the information required under the Act.

(j) Exceptional item is insurance claim realized by company which was in litigation for last five years.

(k) Previous years figures have been recast, regrouped and rearranged wherever necessary.

---

Mar 31, 2015

1 Corporate information

NGL Fine-Chem Limited (CIN L24110MH1981 PLC025884) is a public company domiciled in India and incorporated under the provisions of the Companies Act,1956. Its Shares are listed on Bombay Stock Exchange in India. The Company is engaged in pharmaceutical business. It undertakes manufacturing of wide range of products.

Note 2 Additional information to the financial statements

Particulars For the year ended For the year ended 31 March, 2015 31 March, 2014 Amount (Rs.) Amount (Rs.)

(a) Contingent Liabilities

(i) Disputed direct tax 71,42,270 -

(b) Commitments

(i) Estimated amount of contracts remaining to be executed on capital account and not provided for

Tangible assets 1,33,56,229 14,55,000

(ii) Other commitments (specify nature)

Letters of credit established for which goods are yet to be received and provided for 1,03,37,244 77,61,290

(b) Earnings Per Share

Net profit after tax as per Statement of Profit and Loss attributable to Equity Shareholders 8,33,00,726 4,52,84,554

Weighted average number of equity shares outstanding (Nos) 61,78,024 61,78,024

Basic and diluted earnings per share of the face value of Rs. 5/- each 13.48 7.33

(c) Value of imports calculated on CIF basis:

Raw materials 6,30,41,755 5,62,12,190

Capital goods 24,32,550 10,40,340

Total 6,54,74,305 5,72,52,530

(d) Expenditure in foreign currency:

Professional and consultation fees - -

Other matters 3,85,06,550 2,28,73,238

Total 3,85,06,550 2,28,73,238

(g) Related Parties Disclosures

Disclosures as required by Accounting Standards 18 - "Related Party Disclosures" are given below (a) Related Parties with whom transactions have taken place during the year

(i) Associates Companies/Firms in which Directors or their relatives are interested : Nupur Remedies Private Limited

(ii) Key management personnel and their relatives with whom the company has transacted

Name Designation Relatives

Rahul Nachane Managing Director

Rajesh Lawande Executive Director N G Lawande

(h) Segment Reporting

Based on the guiding principles given by the Accounting Standard - 17, "Segment Reporting" issued by the Institute of Chartered Accountants of India, the company''s business comprises of only one segment - pharmaceuticals. Hence segment wise analysis is not given as the same is not applicable

(i) MSMED Act

The company has not received any information from suppliers or service providers, whether they are covered under the "Micro, Small and Medium Enterprises (Development) Act 2006" (MSMED Act). Therefore it is not possible to give the information required under the Act.

(j) The rate of depreciation for each class of asset has been changed from those prescribed under Schedule VI of the Companies Act 1956 to rates as determined based on the useful life of each class of assets as estimated by the management and considering provisions of Schedule II of the Companies Act 2013. Due to this change, the resulting surplus of depreciation of Rs. 5,76,286 upto 31st March 2014 is adjusted against General Reserve of the Company.

(k) Exceptional item is insurance claim realized by company which was in litigation for last five years.

(l) Previous years figures have been recast, regrouped and rearranged wherever necessary.

---

Mar 31, 2014

1 Corporate information

NIL Fine-Chem Limited (CIN L24110MH1981PLC025884) is a public company domiciled in India and incorporated under the provisions of the Companies Act,1956. Its Shares are listed on Bombay Stock Exchange in India. The Company is engaged in pharmaceutical business. It undertakes manufacturing of wide range of products.

(a) Rights, preferences and restrictions attached to shares

The company has one class of equity shares having a par value of Rs. 5 each. Each shareholder is eligible for one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

2.Terms and conditions of loans

1. Term Loans from Bank of Maharashtra are @ 13.25% interest per annum and repayment to be made in 60 monthly instalments, secured by exclusive mortgage & charge on all of the companys assets including moveable & immovable property, hypothecation of inventories and book debts and guaranteed by Rahul Nachane & Rajesh Lawande, Directors of the company.

2. For Vehicle Loans

(i) Bank of Maharashtra Vehicle loan is at 10.50% interest per annum and repayable in 36 instalments and secured by hypothecation of the vehicle

Repayment Terms :

Secured by exclusive mortgage & charge on all of the companys assets including moveable & immovable property, hypothecation of inventories and book debts and guaranteed by Rahul Nachane & Rajesh Lawande, Directors.

(a) Segment Reporting

Based on the guiding principles given by the Accounting Standard - 17, "Segment Reporting" issued by the Institute of Chartered Accountants of India, the company''s business comprises of only one segment - pharmaceuticals. Hence segment wise analysis is not given as the same is not applicable

(b) MSMED Act

The company has not received any information from suppliers or service providers, whether they are covered under the "Micro, Small and Medium Enterprises (Development) Act 2006" (MSMED Act). Therefore it is not possible to give the information required under the Act.

(c) Previous years figures have been recast, regrouped and rearranged whereever necessary

---

Mar 31, 2013

1 Corporate information

NGL Fine-Chem Limited is a public company domiciled in India and incorporated under the provisions of the Companies Act,1956. Its Shares are listed on Bombay Stock Exchange in India. The Company is engaged in pharmaceutical business. It undertakes manufacturing of wide range of products.

(a) Segment Reporting

Based on the guiding principles given by the Accounting Standard - 17, "Segment Reporting" issued by the Institute of Chartered Accountants of India, the company''s business comprises of only one segment - pharmaceuticals. Hence segment wise analysis is not given as the same is not applicable

(b) MSMED Act

The company has not received any information from suppliers or service providers, whether they are covered under the "Micro, Small and Medium Enterprises (Development) Act 2006" (MSMED Act). Therefore it is not possible to give the information required under the Act.

(c) Previous years figures have been recast, regrouped and rearranged whereever necessary

---

Mar 31, 2012

1 Corporate information

NGL Fine-Chem Limited is a public company domiciled in India and incorporated under the provisions of the Companies Act,1956. Its Shares are listed on Bombay Stock Exchange in India. The Company is engaged in pharmaceutical business. It undertakes manufacturing of wide range of products.

Equity Shares:

The company has one class of equity shares having a par value of 5 each. Each shareholder is eligible for one vote per share held. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

Terms and conditions of loans

1. Term Loans from ICICI bank in previous year carrying interest @ 12.25% and repayment to be made in 20 quarters, secured by exclusive mortgage & charge on all of the companys assets including moveable & immovable property, hypothecation of inventories and book debts and guaranteed by Rahul Nachane & Rajesh Lawande, Directors of the company.

2. Term Loans from Bank of Maharashtra in carrying interest @ 12.50% and repayment to be made in 60 monthly instalments, secured by exclusive mortgage & charge on all of the companys assets including moveable & immovable property, hypothecation of inventories and book debts and guaranteed by Rahul Nachane & Rajesh Lawande, Directors of the company.

3. For Vehicle Loans

(i) ICICI Bank Vehicle loan is at 9.07% interest and repayble in 36 instalments and secured by hypothecation of the vehicle

(ii) HDFC Bank Vehicle loan is at 13.75% interest and repayble in 36 instalments and secured by hypothecation of the vehicle

(a) Segment Reporting

Based on the guiding principles given by the Accounting Standard - 17, "Segment Reporting" issued by the Institute of Chartered Accountants of India, the company's business comprises of only one segment - pharmaceuticals. Hence segment wise analysis is not given as the same is not applicable

(b) MSMED Act

The company has not received any information from suppliers or service providers, whether they are covered under the "Micro, Small and Medium Enterprises (Development) Act 2006" (MSMED Act). Therefore it is not possible to give the information required under the Act.

(c) Previous years figures have been recast, regrouped and rearranged whereever necessary

---

Mar 31, 2011

1. Contingent Liabilities

(i) Estimated amount of contracts remaining to be executed on capital account and not paid for - Rs. 1.13 lakhs (Previous year Rs. 46.87 lakhs)

(ii) Letters of credit established for which goods are yet to be received and provided for - Rs. 50.13 lakhs (Previous year - Rs. 29.09 lakhs).

(iii) Bank Guarantees outstanding - NIL (Previous year - Rs. NIL lakhs).

2. There is no employee drawing remuneration in excess of the limits laid down under Section 217 (2A) of the Companies Act, 1956 read with the Companies (Particulars of Employees) Rules 1975. (Previous year - Nil).

3. Segment Reporting

Based on the guiding principles given by the Accounting Standard - 17 "Segment Reporting" issued by the Institute of Chartered Accountants of India, the companys business comprises of only one segment - pharmaceuticals. Hence segment wise analysis is not given as the same is not applicable.

4. Related parties disclosures

Disclosures as required by Accounting Standards 18 "Related Party Disclosures" are given below:

(a) Related parties with whom transactions have taken place during the year.

Associate Companies/Firms in which Directors or their relatives are interested - NIL

Key management personnel and their relatives with whom company has transacted

Name Designation Relatives

Rahul Nachane Managing Director -

Rajesh Lawande Executive Director N. G. Lawande

A. G. Lawande

5. Retirement benefits:

Short term benefits (Leave encashment)

The company has provided for accumulated compensated absences (leave encashment) as per AS 15 (Revised 2005) Accounting for Retirement Benefits. The provision is made on the basis of the total accumulated leave of employees as on Balance Sheet date valued at the current salary or wage rate. The current years provision is charged under Salaries & Wages amounting to Rs. 21,68,515 (Previous year Rs. 11,77,130).

6. The company has not received any information from suppliers or service providers, whether they are covered under the "Micro, Small and Medium Enterprises (Development) Act 2006". Therefore it is not possible to give the information required under the Act.

7. Value added tax (VAT) recoverable has been recorded on the basis of claims submitted or in the process of being submitted, as per rules of the relevant act and which in the opinion of the company are recoverable.

8. Previous years figures have been recast, regrouped and rearranged wherever necessary.

---

Mar 31, 2010

1. Contingent Liabilities

(i) Estimated amount of contracts remaining to be executed on capital account and not paid for - Rs. 46.87 lakhs (Previous year Rs. 1.06 lakhs)

(ii) Letters of credit established for which goods are yet to be received and provided for - Rs. 29.09 lakhs (Previous year - Rs. 30.85 lakhs).

(iii) Bank Guarantees outstanding - NIL (Previous year - Rs. NIL lakhs).

2. There is no employee drawing remuneration in excess of the limits laid down under Section 217 (2A) of the Companies Act, 1956 read with the Companies (Particulars of Employees) Rules 1975. (Previous year - Nil).

3. Segment Reporting

Based on the guiding principles given by the Accounting Standard - 17 "Segment Reporting" issued by the Institute of Chartered Accountants of India, the companys business comprises of only one segment - pharmaceuticals. Hence segment wise analysis is not given as the same is not applicable.

4. Retirement benefits: Contributions towards gratuity are made to the Employees Group Gratuity Scheme operated by the Life Insurance Corporation of India. The basis of actuarial valuation is given below:

Actuarial assumptions

Mortality rate As per 1994-96 LIC Mortality tables

Withdrawal rate 1% to 3% depending on age

Salary escalation rate 4% for each year

Discounting rate LIC discounting rate (present 8%)

Gratuity benefits As per the Payment of Gratuity Act

1972 as amended from time to time.



Short term benefits (Leave encashment)

The company has provided for accumulated compensated absences (leave encashment) as per AS 15 (Revised 2005) Accounting for Retirement Benefits. The provision is made on the basis of the total accumulated leave of employees as on Balance Sheet date valued at the current salary or wage rate. The current years provision is charged under Salaries & Wages amounting to Rs. 11,77,130 (Previous year Rs. 3,68,099).

5. The company has provided for losses arising from forward contract/derivates in foreign exchange to the extent of Rs. NIL (Previous year - Rs. 1,03,866).

6. The company has not received any information from suppliers or service providers, whether they are covered under the "Micro, Small and Medium Enterprises (Development) Act 2006". Therefore it is not possible to give the information required under the Act.

7. Value added tax (VAT) recoverable has been recorded on the basis of claims submitted or in the process of being submitted, as per rules of the relevant act and which in the opinion of the company are recoverable.

8. Additional information pursuant to provisions of Paragraph 3, 4C and 4D of Part II of Schedule VI to the Companies Act, 1956.

9. Previous years figures have been recast, regrouped and rearranged wherever necessary.

10. Balance Sheet Abstract and Companys General Business Profile:

II. Capital raised during the year (Amount in Rs. thousand)

Public Issue Nil Right Issue Nil

Bonus Issue Nil Private Placement Nil

V. Generic Names of Three Principal Products/Services of Company

Item Code No. Product description

(ITC Code)

292700 Diminazene Aceturate

300939 Diminazene Granules

300939 Pharmaceutical Formulations